Bio-Techne TECH Diagnostics And Genomics — Finitelived Intangible Assets Acquired1

Discontinued — last reported Q2 '22

Similar metrics at other companies

RVTYLife Sciences — Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived

$30.1M—

RVTYDiagnostics — Goodwill, Acquisition

$0—

LHDiagnostics — Goodwill

$5.61B—

ALife Sciences and Diagnostics Markets — Goodwill

$3B-0.1%

CWFinite Lived Intangible Assets - Gross

$1.27B+0.1%

LPLAFinite Lived Intangible Assets - Gross

$4.69B+3.3%

Other financials

Income statement

See full

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

See full

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

See full

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation

See full

Market cap$9.07B-11.8%

Enterprise value$9.15B-13.6%

P/E60.6×+13.6×

P/S7.5×-1.0×

Profitability

See full

Gross margin65%-0.8pp

Operating margin14.2%-7.9pp

Net margin10.9%-6.7pp

FCF margin22.3%+4.0pp

Returns & leverage

See full

Return on equity6.5%-3.9pp

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:FinitelivedIntangibleAssetsAcquired1.

The official record: Bio-Techne’s 10-Q, filed February 7, 2022, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's diagnostics and genomics — finitelived intangible assets acquired1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bio-Techne's diagnostics and genomics — finitelived intangible assets acquired1?: Bio-Techne (TECH) reported diagnostics and genomics — finitelived intangible assets acquired1 of $0 in Q4 2021.
What does diagnostics and genomics — finitelived intangible assets acquired1 mean?: The total value of identifiable intangible assets with a finite useful life acquired through business combinations or asset purchases within the diagnostics and genomics segment. These assets typically include patents, customer relationships, and proprietary technology that are amortized over time.